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BACKGROUND: A nomogram that incorporates traditional and newer prognostic factors to identify patients with chronic lymphocytic
leukemia (CLL) who are at high risk of receiving therapy was developed by investigators at The University of Texas M. D. Anderson
Cancer Center (MDACC). Because the model required validation before its extensive use could be recommended, the authors sought
to externally validate the nomogram in an independent, community-based cohort of patients with CLL. METHODS: In total, 328 previ-
ously untreated patients with newly diagnosed, asymptomatic, Binet stage A CLL from different primary hematology centers who
were registered on a prospective basis during 2006 to 2010 on an observational database of the Italian Lymphoma Study Group
were considered suitable for external validation of the model. RESULTS: A total point score was calculated for each patient using a
formula proposed by MDACC investigators, and the median score was 19.9 (range, 0-69.5). Furthermore, when the score was eval-
uated as continuous variable (ie, by measuring the risk of each point increase), the total point score was associated with the time to
first treatment (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.02-1.05; P < .0001). Receiver operating characteristic analysis
identified a point score of 25 (area under curve; 0.64; sensitivity, 61.5; specificity, 72.1; P < .0001) as the best threshold capable of sep-
arating patients who needed therapy from patients who did not (HR, 3.27; 95% CI, 2,07-5.18; P < .0001). The prognostic index cate-
gory also remained a predictor of the time to first treatment when the analysis was limited to patients with Rai stage 0 disease (HR,
4.05; 95% CI, 2.25-7.52; P < .0001). Finally, a goodness-of-fit test demonstrated that the nomogram model had a significantly good
fit at 2 years (correlation coefficient [r2] ¼ 0.966; P ¼ .002). CONCLUSIONS: The current results confirmed the ability of a
newly developed prognostic index to predict the time to first treatment among previously untreated patients with CLL who had early
disease and extended the utility of the model to those with Rai stage 0 disease. In addition, the actual and predicted time to
first treatment outcomes revealed good agreement, suggesting that, externally, the results provided by the model are well calibrated.
Cancer 2013;119:1177-85.VC 2012 American Cancer Society.
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INTRODUCTION
In parallel with significant improvements in treatment outcomes, there has been dramatic progress in understanding the
biology of chronic lymphocytic leukemia (CLL), and several new prognostic factors have been identified.1 However, it is
important to clearly define the clinical endpoint for analysis and not to assume that the same factors apply across all clinical
endpoints.2 Recently, Wierda et al3 performed an analysis to identify traditional and newer prognostic factors that are
associated independently with the time to first treatment for patients with CLL who do not have an indication for treat-
ment at the time of presentation. On the basis of their findings, a nomogram was developed that calculates the 2-year and
4-year probability of treatment and estimates the median time to first treatment.3
Caution must be used when extrapolating results from regression models that are built on different populations,
because a nomogram derived from a certain patient cohort may not be applicable to an independent cohort. Conse-
quently, external validation is essential to ensure that the nomogram is completely applicable to clinical practice and an
extensive clinical use can be recommended.4
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In the current study, we used the Italian Lymphoma
Study Group (GISL) database to validate the model pro-
posed by investigators at The University of Texas M. D.
Anderson Cancer Center (MDACC) for assessing the
time to first treatment in patients with CLL. It is notewor-
thy that our independent, prospective, multicenter series
consisted of community-based patients who had early
stage disease at presentation.3 We also extended the utility
of the index to patients with Rai stage 0 disease, who rep-
resent approximately 70% of patients with newly diag-
nosed early CLL in nonreferral primary hematology
centers in Italy.5 Finally, because, in their original study,
Wierda et al3 did not identify a test group of patients to
internally validate their nomogram, the results of the cur-
rent study represent the first valid attempt to verify the
reliability of the newly proposedMDACC index.
MATERIALS AND METHODS
Patients
Three hundred twenty-eight patients with previously
untreated, Binet stage A CLL from several institutions who
were diagnosed between January 2006 and December
2010 were registered prospectively within 12 months from
diagnosis in a national database (O-CLL1 protocol; clini-
caltrial.gov identifier NCT00917540). The median time
elapsed between the date of diagnosis and the date of data-
base registration was 3 months (range, <1-12 months).
The date of CLL diagnosis was recorded, and the time-to-
event endpoint was defined as the time elapsed between the
time of database registration and the time of first CLL
treatment. The inclusion criteria for CLL diagnosis, which
were used at the time of study design and initiation, fol-
lowed the National Cancer Institute-sponsored Working
Group guidelines,6 which require absolute lymphocytosis
with a lower threshold of >5000 mature-appearing lym-
phocytes/mL in the peripheral blood. Because the objective
of this observational study was to evaluate the role of novel
prognostic variables in younger patients with CLL, only
those aged<70 years were considered eligible.
Diagnoses were centrally confirmed with flow
cytometry (positive for cluster of differentiation 5 [CD5;
a type I transmembrane protein]/weak expression of sur-
face membrane immunoglobulin [SmIg]) by a biologic
review committee according to flow cytometric analyses
that were centralized at the National Institute of Cancer
Laboratory in Genoa. Both traditional and newer prog-
nostic parameters were assessed at the time of database
registration. Evaluations of newer prognostic factors,
including immunoglobulin heavy-chain variable gene
(IgHV) mutation status, CD38 (glycoprotein) expression,
and f-chain–associated protein kinase 70 (ZAP-70)
expression, by flow cytometry and Western blot analysis
were centralized at the National Institute of Cancer Labo-
ratory in Genoa; and the study of chromosome abnormal-
ities by fluorescence in situ hybridization (FISH) analysis
was centralized at the Research Center for the Study of
Leukemia, Institute for Cancer Research and Treatment
Foundation at the University of Milan. Information
regarding traditional prognostic factors and clinical and
laboratory variables was obtained at the local hematology
centers and included sex, age, Rai stage, the number of
involved lymph node sites (cervical, axillary, and inguinal)
and size (ie, greatest dimension in cm), measurement of
liver and spleen size, absolute lymphocyte count, hemo-
globin level, platelet count; b2-microglobulin, and lactate
dehydrogenase (LDH).
The expression of CD38 was analyzed by 3-color im-
munofluorescence, and ZAP-70 was detected according to
previously reported methods.7 The cutoff level of 30% pos-
itive cells was chosen to discriminate CD38-negative CLL
from CD38-positive CLL.6 Cutoff levels of 20% or 30%
were used to distinguish ZAP-70-negative CLL from ZAP-
70-positive CLL, depending on the anti–ZAP-70 antibody
used and the laboratory’s standardization of ZAP-70 flow
cytometric protocols.6 IgHV gene presence and mutation
status were determined using combinational DNA accord-
ing to previously published methods.7-9
Interphase FISH analyses were carried out for the
detection of trisomy 12 and chromosome deletion at
17p13.1, 11q22.3, and 13q14.3 loci. Dual-color hybrid-
izations, using appropriate centromeric-specific probes and
unique, sequence-specific probes for the tumor protein 53
(TP53) (locus-specific identifier probe [LSI] P53) and
ataxia telangiectasia mutated (ATM) (LSI ATM) loci, were
performed for the 17p13.1 and 11q23.3 deletions, respec-
tively.10 To detect the 13q14.3 deletion, the LSI D13D25
was cohybridized with the 13q34 telomeric probe as an in-
ternal control for nullisomy. A chromosome 12-specific a-
satellite probe was used to identify trisomy 12. All probes
were purchased from Vysis Inc. (Downers Grove, Il), and
FISH procedures were performed according to the manu-
facturer’s specifications. For each hybridization, we assessed
a minimum of 200 interphase nuclei.8 Patients were cate-
gorized into high-risk (17p13.1 and 11q22.3 deletions), in-
termediate-risk (trisomy 12), and low-risk (13q14.3
deletion and normal) groups for subsequent analysis.
Indication for Therapy
All patients underwent sequential monitoring and were
managed according to a ‘‘watch-and-wait’’ policy.
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The frequency of follow-up visits was individualized
according to patient risk and ranged between 3 months
and 6 months (median, 3 months). All physicians who
registered patients into this observational database stated
that they had used the National Cancer Institute-spon-
sored Working Group guidelines as reference criteria for
starting therapy.6,11 The absolute lymphocyte count was
not used as the sole indicator for treatment. Active disease
that required therapy was defined on the basis of at least 1
of the criterion set out in the National Cancer Institute-
sponsoredWorking Group guidelines.6,11
The Wierda et al Nomogram Score
The variables required for the Wierda et al3 nomogram
were the number of lymph node sites involved, the size of
cervical lymph nodes, LDH level, IgVHmutational status,
and the presence of 11q or 17p deletion established by
FISH analysis. A visual representation of the relative con-
tribution of each prognostic factor to the total point score
is illustrated in Figure 1.
The formula for calculating the total point score for
each patient is as follows: [I(no. of lymph node sites
involved ¼ 3)  7.370 þ I(FISH ¼ 11q del)  9.312 þ
I(FISH ¼ 17p del)  11.285 þ (greatest dimension of
largest cervical lymph node in cm)  4.172 þ (LDH/
100)  I([IgHV gene ¼ mutated]  5.000 þ (LDH 
100)  I(IgHV gene ¼ unmutated)  1.065) þ 35.467.
The indicator function (I) is equal to 1 if the statement in
the parentheses is true and, otherwise, is equal to zero.
Statistical Analyses
The primary endpoint, time to first treatment, was
defined as the interval between the date of database regis-
tration and date of first CLL treatment. Patients who did
not receive any treatment were censored at their last con-
firmed treatment-free follow-up date. The Kaplan-Meier
method was used to estimate distribution of the time to
first treatment, and the log-rank test was used to compare
patient subgroups. Likelihood-ratio tests were used to test
the effects of individual factors, either in univariate analy-
sis or jointly. Hazard ratios (HRs) and confidence inter-
vals (CIs) for HRs were calculated from the Cox models.
Nomogram validation consisted of discrimination
and validation. Discrimination, which refers to the nomo-
gram model’s ability to correctly distinguish 2 classes of
outcome, was quantified by means of the concordance
index (the Harrell C-statistic).12 We used the area under
the receiver operating characteristic curve (AUC) was to
measure model discrimination. The AUC can range from
0.5 (which indicates a test with no information) to 1.0
(which indicates a perfect test).
We also assessed the nomogram calibration that
compares the predicted and actual time to first treatment.
For this purpose, a Poisson log-linear model was used.
RESULTS
Patient Characteristics
In total, 328 patients were included in this analysis. The
median age at diagnosis was 61 years (range, 33-70 years),
and 58.2% were men. The majority of patients had Rai
stage 0 disease (76.5%), and virtually all were local, non-
referred patients who were first diagnosed and then man-
aged at different primary Italian hematology centers. In
this patient cohort, 33.4% had unmutated IgVH status,
and 9.7% had high-risk cytogenetic features (ie, 17p or
11q deletion) (Table 1).
Patients were followed for a total of 2038 person-
years (median, 30 months; range, 1-65 months), during
which 68 patients (20.7%) required therapy. The proba-
bility of remaining free from therapy was 57% at 5 years,
and no plateau was reached (Fig. 2). When the analysis
was restricted to patients who received therapy, the me-
dian time to treatment was 24 months (range, 2-56
months).
Univariate and Multivariate Analysis
Univariate analysis of the time to first treatment included
a series of traditional and novel variables. Traditional clin-
ical and laboratory parameters that were associated with a
shorter time to first treatment were a higher absolute
Figure 1. This chart illustrates the nomogram proposed by
Wierda et al3 for the time to first treatment (Wierda WG,
O’Brien S, Wang X, et al. Multivariate model for time to first
treatment in patients with chronic lymphocytic leukemia. J
Clin Oncol. 2011;29:4088-4095). LN indicates lymph node;
LDH, lactate dehydrogenase; IGHV, immunoglobulin heavy-
chain variable region genes; FISH, fluorescence in situ
hybridization.
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lymphocyte count (P< .0001), increased b2-microglobu-
lin (P < .0001), advanced Rai substage (P < .0001), and
multiple lymph node involvement (P < .0001). With
regard to novel prognostic variables, we observed that the
presence of 11q or 17p deletion by FISH analysis identi-
fied a patient subset at higher risk of requiring early treat-
ment (P¼ .002) (Fig. 3).13 Also, patients with unmutated
IgVH status (P< .0001) or CD38 expression (P< .0001)
had a shorter time to first treatment. Regardless of the
method used for ZAP-70 assessment (ie, flow cytometry
or Western blot analysis), a close correlation with the time
to first treatment was observed (P < .0001 for both).
However, ZAP-70 expression was not included in the
multivariable analysis because of a lack of standardized
testing in the community. Among the variables that were
significant in univariate analysis, only Rai substages (P ¼
.01), absolute lymphocyte count (P < .0001), IgVH
TABLE 1. Patient Characteristics and Univariate Analysis of the Time to First Treatment
Characteristic Median (Range) HR [95% CI] P
Age, y 61 (33-70) 0.99 [0.97-1.02] .77
ALC, 109/L 6.6 (0.4-110) 1.03 [1.02-1.04] < .0001
b2-Microglobulin, mg/L 1.8 (0.1-4.0) 2.43 [1.69-3.49] < .0001
LDH, IU/L 325 (74-856) Abnormal vs normal: 1.94 [0.88-4.26] .13
Spleen size, cm 0 (0-12) 2.0 [0.87-4.63] .10
Liver size, cm 0 (0-8) 1.27 [0.71-2.26] .42
Cervical lymph node size, cm 0 (0-6) 1.19 [0.69-1.81] .65
Characteristic No. of Patients (%) HR [95% CI] P
Sex
Men 191 (58.2) 1.01 [0.64-1.60] .95
Women 137 (41.8) Ref
Rai stage
0 251 (76.5) Ref
I-II 77 (23.5) 2.58 [1.64-4.05] < .0001
No. of involved LND sites
0 268 (81.7) Ref
1 45 (13.7) 2.34 [1.39-3.94] .001
2 15 (4.5) 3.55 [1.60-7.85] .002
IGHV mutation status
Unmutated 109 (33.4) 2.03 [1.61-2.56] < .0001
Mutated 217 (66.6) Ref
Hierarchic FISH category
Deletion of 17p or 11q 32 (9.7) 2.13 [1.12-4.06] .02
Trisomy 12 36 (10.9) 1.22 [0.61-2.42] .58
Negative 113 (34.5) 0.79 [0.45-1.39] .41
Deletion of 13q 147 (44.8) Ref
CD38 expression
Positive: 30% 70 (21.3) 3.11 [1.97-4.89] < .0001
Negative: <30% 258 (78.6) Ref
ZAP-70: Western blot analysis
Strong 145 (44.2) 2.48 [1.59-3.94] < .0001
Negative/weak 183 (55.7) Ref
Abbreviations: ALC, absolute lymphocyte count; CD38, cluster of differentiation 38 (cyclic adenosine diphosphate ribose hydrolase); CI, confidence interval;
FISH, fluorescence in situ hybridization; HR, hazard ratio; IGHV, immunoglobulin heavy chain variable region; LDH, lactate dehydrogenase; LND, lymph node;
Ref, referent category; ZAP-70, zeta-chain associated protein 70.
Figure 2. This is a Kaplan-Meier estimate of the time to first
treatment for 328 patients with Binet stage A chronic lym-
phocytic leukemia.
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mutation status (P < .0001), and b2-microglobulin (P <
.05) retained independent prognostic significance for the
time to first treatment.
Validation of the Wierda et al Nomogram
In each of the 328 patients with Binet stage A disease, we
calculated the total point score using the formula pro-
posed by Wierda et al.3 Total point scores ranged from 0
to 69.5 (median, 19.9) and were similar to the total point
scores reported by the MDACC group (median, 21.0;
range, 0-87.4).3
We wondered whether the Wierda et al nomogram3
could predict the time to first therapy in our patient cohort.
The total point score, as a continuous variable (ie, meas-
uring the risk of each point score increase), was associated
with the time to first treatment (HR, 1.04; 95% CI, 1.02-
1.05; P < .0001). In addition, we conducted a C-statistic
analysis, which is considered a measure of concordance
between observed and predicted time-dependent events.
The results from that analysis clearly demonstrated that the
total point score correctly predicted the time to first treat-
ment (C¼ 0.62; 95%CI, 0.55-0.70).
Next, we investigated the threshold value that best
differentiated patients who required treatment from
patients who had stable disease. A receiver operating char-
acteristic analysis performed for this purpose identified a
point score of 25 (AUC, 0.64; sensitivity, 61.5; specificity,
72.1; P < .0001) (Fig. 4) as the best threshold capable of
discriminating patients who needed therapy from patients
who did not. A graphic representation illustrating how
this threshold works in predicting the time to first treat-
ment is presented in Figure 5. The likelihood of treatment
for patients with total point scores 25 was substantially
greater than that of patients with total point scores <25
(HR, 3.27; 95% CI, 2.07-5.18; P < .0001), as indicated
in Figure 5. This threshold allowed an accurate prediction
of the time to first treatment (C ¼ 0.65; 95% CI, 0.57-
0.71); and, during the first 5 years of follow-up, the esti-
mated rate of progression to an active phase of the disease
requiring treatment was approximately 1.8% (95% CI,
1.6%-1.9%) per year among patients who had total score
points<25, whereas the estimate increased to 2.5% (95%
CI, 2.2%-2.8%) per year for patients who had total point
scores25.
Figure 3. The time to first treatment is illustrated according
to the results of fluorescence in situ hybridization (FISH)
analysis. Kaplan-Meier estimates are shown for each FISH
category according to the hierarchic categorization published
by Dohner et al14 (Dohner H, Stilgenbauer S, Benner A, et al.
Genomic aberrations and survival in chronic lymphocytic leu-
kemia. N Engl J Med. 2000;343:1910-1916).
Figure 4. A receiving operating characteristic (ROC) analysis of
the accuracy of the total point score is illustrated. Accuracy is
measured by calculating the area under the ROC curve (AUC).
Figure 5. This is a Kaplan-Meier estimate of the time to first
treatment by prognostic index category (ie, total point score
<25 or 25) in patients with Binet stage A chronic lympho-
cytic leukemia.
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A calibration of the Wierda et al3 nomogram was
assessed by comparing the nomogram that predicted the
time to first therapy with the actual time to first therapy in
patient subgroups divided by decades according to their
total point score. This was verified by a linear analysis,
and the goodness-of-fit test indicated that the nomogram
had a significantly good fit at 2 years (correlation coeffi-
cient [r2] ¼ 0.966; P ¼ .002) (Fig. 6), which means that
the model was accurate in predicting the individual 2-year
time to treatment in the external validation set. We
avoided evaluating the fit of the model at 4 years, because
only 44 patients had a follow-up>48 months.
Because Rai stage 0 accounted for >76.5% of
patients in our cohort with early stage CLL, we wondered
whether the Wierda et al3 nomogram also would retain its
discriminant power in this patient subset. When 251
patients with Rai stage 0 CLL in the current series were
classified according to the previously identified threshold
(ie, a point score of 25), we observed that 66.9% fell into
the low-risk category, and 33% fell into the high-risk cate-
gory. Differences in the time to first treatment were
observed between patients with Rai stage 0 disease based
on whether they were classified as a low risk or high risk
according to the nomogram score (HR, 4.05; 95% CI,
2.25-7.52; P< .0001) (Fig. 7), indicating that theWierda
et al3 nomogram accounts, at least in part, for some of the
heterogeneity in clinical outcomes observed within clini-
cal stage categories. Finally, the total point score also per-
mitted us to accurately predict the time to first treatment
among patients with Rai stage 0 disease (C ¼ 0.65; 95%
CI, 0.56-0.74).
Wierda et al Score and Patients Requiring
Therapy
The interaction between the Wierda et al3 nomogram cat-
egories and the time to first treatment was assessed in
patients who had progressive disease that required ther-
apy. Theoretically, we expected that the time to first treat-
ment would be longer for patients in the low-risk category
and shorter for patients in the high-risk category. In our
experience, the median time to first treatment for 68
patients who required therapy, when stratified according
to the Wierda et al3 nomogram into 2 groups with total
point scores <25 (n ¼ 30) and >25 (n ¼ 38), was virtu-
ally the same (median time to first treatment, 24 months
for both; HR, 1.19; 95% CI, 0.74-1.99; P ¼ .43). This
observation suggests that, in patients with early stage CLL
who eventually require therapy, the Wierda et al nomo-
gram3 does not help to identify patient subsets that have
different patterns of progression.
DISCUSSION
Previous published reports evaluated the impact of either
clinical or biologic prognostic factors on the clinical out-
come of patients with CLL.14-22 Further work was per-
formed to combine clinical variables in a prognostic index
that was able to predict overall survival more accurately
than clinical stage alone.23 The model was subsequently
validated by different groups,5,24 and a revised version of
this score was useful to predict the time to first treatment
in a previously published series5 and in the current patient
Figure 6. This chart illustrates the calibration of validation
data using the nomogram published by Wierda et al3 (Wierda
WG, O’Brien S, Wang X, et al. Multivariate model for time to
first treatment in patients with chronic lymphocytic leukemia.
J Clin Oncol. 2011;29:4088-4095). The goodness of fit test
revealed that the nomogram model had significantly good fit
at 2 years (correlation coefficient [r2] ¼ 0.966; P ¼ .002). TFT
indicates time to first treatment.
Figure 7. This is a Kaplan-Meier estimate of the time to first
treatment according to prognostic index category (ie, total
point score <25 or 25) in patients with Rai stage 0 chronic
lymphocytic leukemia.
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cohort. Indeed, the 2-year probability of remaining free
from therapy was 93%, 85%, and 63%, in patients who
scored 0 to 2, 3 or 4, and 5 to 7, respectively (chi-square
test for trend, 9.94; 1 degree of freedom; P¼ .001). How-
ever, currently, the inclusion of traditional and newer
prognostic factors in the same model is a novelty.3
Remarkably, the time to first treatment is a more suitable
clinical endpoint than overall survival for patients with
early CLL, because it does not reflect competing risks
between successive relapses, histologic transformation,
deaths in remission, or the impact of new therapies.5
The current results obtained in an independent
patient cohort confirm the ability of the model recently
developed by Wierda et al3 to predict the time to first
treatment among patients with previously untreated CLL
who have early disease. The challenges for this type of
analysis include subjectivity in computing some of the pa-
rameters evaluated, like assessing bulk of disease by meas-
uring lymph nodes and organomegaly by physical
examination. It should be pointed out that palpation and
measures of lymph node, liver, and spleen size are some-
what subjective, approximate, and may limit the precision
of prognostic tools. In addition, the nomogram is a
graphic representation, which potentially is less accurate
than using a tool that is purely calculated. When Wierda
et at3 evaluated the parameters, they included either Rai
stage in the model or hemoglobin level and platelet count,
because there are significant interactions between these
parameters. Our analyses, which extend the utility of the
MDACC score to a homogeneous subset of patients with
Rai stage 0 disease, support the value of the model above
the possible interactions between different parameters.
Although our findings indicate that this prognostic
index is a significant advance in predicting the time to first
treatment in patients with early CLL, several qualifica-
tions are required. For instance, in multivariate analysis of
the time to first treatment, we observed that only 4 covari-
ates had independent prognostic value (ie, Rai stage, abso-
lute lymphocyte count, IgVH mutation status, and b2-
microglobulin). In contrast, theMDACC study identified
5 covariates with independent prognostic value, which
were included in the nomogram: the size of cervical lymph
nodes, the number of lymph node areas, FISH abnormal-
ities, LDH concentration, and IgVH mutation status.3
These changes reflect the different distribution of either
traditional or newer prognostic variables among patients
registered in our observational database compared with
patients in the MDACC database. Actually, only 36% of
patients evaluated at the MDACC had Rai stage 0 CLL;
whereas, in our prospective multicenter patient cohort,
Rai stage 0 accounted for 76.5% of all cases. Differences
also were observed when the distribution of patients dis-
playing mutated IgVH status (GISL cohort, 66.6%;
MDACC cohort, 55%) or low-risk genetic features
defined on the basis of the presence of 13q deletion or
normal cytogenetics (GISL cohort,79.2%; MDACC
cohort 69%), was compared between the 2 series.
The current analysis has some weakness. First,
patients enrolled in our prospective database were selected
intentionally on the basis of an age threshold of 70
years, because we wanted to specifically address the issue
of prognosis in younger patients who were diagnosed with
early stage CLL. Few studies have evaluated interactions
between age and the utility of prognostic testing, because
it is not completely clear whether age may determine dif-
ferences in the natural history of CLL.23-25 Our study
reinforces the need to generate prognostic models that
include mostly younger CLL patients. Conversely, recent
findings suggest that prognostic assessment has little value
in patients aged 75 years.25 However, given the avail-
ability of newer and less toxic therapies, even for older
patients,26 and because the average median age of patients
with CLL is 72 years, it also would be relevant to validate
the Wierda et al3 model in a patient cohort that includes
all age groups of patients with CLL. Second, the current
validation analysis was performed on a relatively small
patient series. Indeed, our cohort, which included 328
patients with CLL, was 2 times smaller than the cohort
analyzed by MDACC investigators, who evaluated 687
patients to generate the model.3 Although this is a limit-
ing factor, some aspects of our patient cohort, such as the
homogenous disease stage of patients, the prospective na-
ture of enrolment, and the community-based setting, sup-
port our current results. Finally, we need to emphasize
that this represents the first reliable attempt to validate the
MDACC model, because Wierda et al,3 in their original
study, did not identify a patient test group to internally
validate the nomogram.
Our study has several important strengths. All
patients had early stage disease at the time of entry into
the study and, thus, represent the group of patients for
whom prognostic instruments are most needed. Accord-
ingly, validation of the nomogram proposed by
MDACC3 meets the need to separate Binet stage A
patients into different prognostic groups to devise individ-
ualized and tailored follow-up policies during the treat-
ment-free period. In addition, in Italy, patients
undergoing clinical evaluation for absolute lymphocytosis
commonly are referred to primary hematology centers.
For that reason, clinical studies that include these patients
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allow for a horizontal, long-term, observational follow-up
from early diagnosis representative of the natural course
of CLL.5 The same does not always apply for studies deal-
ing with patients who are followed at academic referral
centers in the United States in view of the influence of
both lead-time and time-length bias.23,24
In recent years, statistical prediction models have
been developed across the majority of cancer types.27-29
One such predictive tool is the nomogram, which creates
a simple representation of a statistical predictive model
that generates a numerical probability of a clinical event.
The external validation of the MDACC nomogram we
carried out in an independent, community-based cohort
of patients with CLL supports the accuracy of the method
used to generate the model. Furthermore, the actual and
predicted time-to-first-treatment outcomes revealed good
agreement, suggesting that time-to-first-treatment predic-
tions from the nomogram are well calibrated. It should be
pointed out, however, that the particularly significant
good fit of the model at 2 years may be caused, at least in
part, by the relatively short median follow-up of our
patient cohort (ie, 30 months).
In conclusion, the nomogram proposed by Wierda
et al3 can be considered a trade-off between a complex
mathematical formulas and a simple numerical estimate.
External validation of this nomogram may contribute to-
ward expanding its diffusion among clinicians. However,
we expect that the availability of a web-based version defi-
nitely may facilitate its current use in clinical practice and
among patients who are seeking reliable information
about the clinical outcome of CLL, especially when it is
diagnosed at an early phase of the disease.
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